MilliporeSigma Webinars

31. Key Benefits Of PCR-Based mRNA Manufacturing For Clinical Development 6/12/2023

    To unlock the potential of your mRNA therapies and accelerate your development and manufacturing program, discover the benefits of a novel PCR-based mRNA drug substance manufacturing process.

32. Establishing Analytical Methods For Emerging mRNA-Based Therapies 6/5/2023

    Here, we describe the use of cutting-edge technologies to assess critical quality attributes of both mRNA drug substances and drug products.

33. Monitoring And Quality Control Of Cell Culture Media Preparation 3/8/2023

    Explore the possibilities of using Raman spectroscopy for the quality control of cell culture media preparation, the benefits of using this technology at this step, and the demonstrated performances.

34. Developing Modular Facility Proof-Of-Concept For Multi-Modal Bioprocessing 2/2/2023

    Learn about the innovative solution of designing and constructing manufacturing facilities using predesigned and prefabricated elements.

35. RNA Interference - From Single Gene Studies To Whole Genome Screens 11/7/2022

    Endoribonuclease-prepared siRNAs (esiRNAs) are able to overcome the limitations of RNAi. Learn about esiRNAs, their advantages over standard siRNAs, and ways this technology is utilized in different research fields.

36. Identity Testing By NGS As A Means Of Risk Mitigation For Viral Gene Therapies 6/17/2022

    This presentation explores regulatory requirements for identity testing, NGS applications for identity testing as compared to traditional methods, and the impact of not establishing a proper risk-based testing strategy.

     

37. Application Of Two-Dimensional Chromatography To Improve Productivity Of Analytical Testing Of Cell & Gene Therapy Products 10/13/2021

    Analytical characterization of cell and gene therapy products remains a challenging, costly, and time-consuming task. In this video we present a proof-of-concept work demonstrating application of multidimensional chromatography for characterization of Adenovirus type 5 (Ad5)-based product that not only allowed increased productivity, but also limits the sample volume needed for the analysis.

38. AAV Gene Therapy: Orthogonal Methods To Understand And Define CQAs 10/13/2021

    As with all biopharmaceuticals, it is important to identify and monitor the critical quality attributes (CQAs) of these products to ensure their safety and efficacy. Our experts present a range of orthogonal methods to understand and define the CQAs of AAV products.

39. Achieving High Yields In Scalable Xeno-Free Culture Formats With Mesenchymal Stem Cell Medium 7/27/2021

    In this webinar, we will explore the current landscape and future trends of cell culture media for adult mesenchymal stem cells and discuss the options to derive MSC’s from bone marrow in xeno-free conditions from static to microcarrier-based suspension culture platforms. Finally, we will demonstrate the Stemline^® XF MSC Media we’ve developed to reduce scalability roadblocks while maintaining robust performance.

40. Which Ingredient Are You Missing In Your Gene Therapy Success Recipe? 3/25/2021

    In this podcast, Ratish Krishnan, Associate Director for Cell & Gene Therapy talks about the tremendous promise gene therapies have for changing the healthcare paradigm and solutions to some of the biggest challenges in gene therapy manufacturing.